A Phase 1b Parallel Cohort Study Evaluating the Efficacy and Safety of Momelotinib and Momelotinib Combined With Trametinib in Subjects With Metastatic KRAS-mutated Non-Small Cell Lung Cancer (NSCLC) Who Have Failed Platinum-Based Chemotherapy Preceded by a Dose-finding Lead-in Phase
Phase of Trial: Phase I
Latest Information Update: 07 Feb 2019
Price : $35 *
At a glance
- Drugs Momelotinib (Primary) ; Trametinib
- Indications Non-small cell lung cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors Gilead Sciences; Sierra Oncology
- 24 Mar 2017 Status changed from active, no longer recruiting to discontinued.
- 04 Aug 2016 Planned End Date changed from 1 Mar 2017 to 1 Apr 2017.
- 13 May 2016 Planned End Date changed from 1 Mar 2018 to 1 Mar 2017.